Alan Crossman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Millan Mark J; Svenningsson Per; Ashby Charles R; Hill Michael; Egeland Martin; Dekeyne Anne; Brocco Mauricette; Di Cara Benjamin; Lejeune Françoise; Thomasson Nitza; Munoz Carmen; Mocaër Elisabeth; Crossman Alan; Cistarelli Laetitia; Girardon Sylvie; Iob Loretta; Veiga Sylvie; Gobert Alain
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Scholz Birger; Svensson Marcus; Alm Henrik; Sköld Karl; Fälth Maria; Kultima Kim; Guigoni Céline; Doudnikoff Evelyne; Li Qin; Crossman Alan R; Bezard Erwan; Andrén Per E
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
Aubert Incarnation; Guigoni Céline; Li Qin; Dovero Sandra; Bioulac Bernard H; Gross Christian E; Crossman Alan R; Bloch Bertrand; Bezard Erwan
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Alan Crossman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Millan Mark J; Svenningsson Per; Ashby Charles R; Hill Michael; Egeland Martin; Dekeyne Anne; Brocco Mauricette; Di Cara Benjamin; Lejeune Françoise; Thomasson Nitza; Munoz Carmen; Mocaër Elisabeth; Crossman Alan; Cistarelli Laetitia; Girardon Sylvie; Iob Loretta; Veiga Sylvie; Gobert Alain
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
The Journal of pharmacology and experimental therapeutics 2008;324(2):600-11.
2008: Scholz Birger; Svensson Marcus; Alm Henrik; Sköld Karl; Fälth Maria; Kultima Kim; Guigoni Céline; Doudnikoff Evelyne; Li Qin; Crossman Alan R; Bezard Erwan; Andrén Per E
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
PloS one 2008;3(2):e1589.
2007: Aubert Incarnation; Guigoni Céline; Li Qin; Dovero Sandra; Bioulac Bernard H; Gross Christian E; Crossman Alan R; Bloch Bertrand; Bezard Erwan
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Biological psychiatry 2007;61(7):836-44.
2007: Scheller Dieter; Chan Piu; Li Qin; Wu Tao; Zhang Renling; Guan Le; Ravenscroft Paula; Guigoni Celine; Crossman Alan R; Hill Michael; Bezard Erwan
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
Experimental neurology 2007;203(2):415-22.
2006: Hill Michael P; Ravenscroft Paula; McGuire Steven G; Brotchie Jonathan M; Crossman Alan R; Rochat Catherine; Millan Mark J
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Movement disorders : official journal of the Movement Disorder Society 2006;21(12):2090-5.
2006: Nadjar Agnes; Brotchie Jonathan M; Guigoni Celine; Li Qin; Zhou Shao-Bo; Wang Gui-Jie; Ravenscroft Paula; Georges François; Crossman Alan R; Bezard Erwan
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006;26(34):8653-61.
2005: van der Stelt Mario; Fox Susan H; Hill Michael; Crossman Alan R; Petrosino Stefania; Di Marzo Vincenzo; Brotchie Jonathan M
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(9):1140-2.
2005: Silverdale Monty A; Nicholson S L; Crossman A R; Brotchie J M
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(4):403-9.
2005: Hallett P J; Dunah A W; Ravenscroft P; Zhou S; Bezard E; Crossman A R; Brotchie J M; Standaert D G
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Neuropharmacology 2005;48(4):503-16.
2005: Guigoni Céline; Li Qin; Aubert Incarnation; Dovero Sandra; Bioulac Bernard H; Bloch Bertrand; Crossman Alan R; Gross Christian E; Bezard Erwan
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(8):2102-7.
2004: Ismayilova Naila; Crossman Alan; Verkhratsky Alexei; Brotchie Jonathan
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats.
European journal of pharmacology 2004;497(2):187-95.
2004: Nash J E; Ravenscroft P; McGuire S; Crossman A R; Menniti F S; Brotchie J M
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Experimental neurology 2004;188(2):471-9.
2004: Hill Michael P; Brotchie Jonathan M; Crossman Alan R; Bezard Erwan; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.
Clinical neuropharmacology 2004;27(4):171-7.
2004: Silverdale M A; Nicholson S L; Ravenscroft P; Crossman A R; Millan M J; Brotchie J M
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Experimental neurology 2004;188(1):128-38.
2004: Hill Michael P; Ravenscroft Paula; Bezard Erwan; Crossman Alan R; Brotchie Jonathan M; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
The Journal of pharmacology and experimental therapeutics 2004;310(1):386-94.
2004: Millan Mark J; Di Cara Benjamin; Hill Michael; Jackson Michael; Joyce Jeffrey N; Brotchie Jonathan; McGuire Steve; Crossman Alan; Smith Lance; Jenner Peter; Gobert Alain; Peglion Jean-Louis; Brocco Mauricette
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):921-35.
2004: Fox Susan; Silverdale Montague; Kellett Mark; Davies Rhys; Steiger Malcolm; Fletcher Nicholas; Crossman Alan; Brotchie Jonathan
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(5):554-60.
2004: Bezard Erwan; Hill Michael P; Crossman Alan R; Brotchie Jonathan M; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
European journal of pharmacology 2004;485(1-3):159-64.
2004: Ravenscroft Paula; Chalon Sylvie; Brotchie Jonathan M; Crossman Alan R
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Experimental neurology 2004;185(1):36-46.
2003: Hill Michael P; Bezard Erwan; McGuire Steven G; Crossman Alan R; Brotchie Jonathan M; Michel Ann; Grimée Renee; Klitgaard Henrik
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
Movement disorders : official journal of the Movement Disorder Society 2003;18(11):1301-5.
2003: Henry Brian; Duty Susan; Fox Susan H; Crossman Alan R; Brotchie Jonathan M
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Experimental neurology 2003;183(2):458-68.
2003: Savola Juha-Matti; Hill Michael; Engstrom Mia; Merivuori Hannele; Wurster Siegfried; McGuire Steven G; Fox Susan H; Crossman Alan R; Brotchie Jonathan M
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2003;18(8):872-83.
2003: Segovia Gregorio; Mora Francisco; Crossman Alan R; Brotchie Jonathan M
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2003;18(2):138-49.
2003: Silverdale Monty A; Fox S H; Crossman A R; Brotchie J M
Potential nondopaminergic drugs for Parkinson's disease.
Advances in neurology 2003;91():273-91.
2002: Fox Susan H; Henry Brian; Hill Michael; Crossman Alan; Brotchie Jonathan
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(6):1180-7.
2002: Silverdale M A; Crossman A R; Brotchie J M
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Experimental neurology 2002;174(1):21-8.
2002: Fox Susan H; Kellett Mark; Moore A Peter; Crossman Alan R; Brotchie Jonathan M
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
Movement disorders : official journal of the Movement Disorder Society 2002;17(1):145-9.
2001: Sieradzan K A; Fox S H; Hill M; Dick J P; Crossman A R; Brotchie J M
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Neurology 2001;57(11):2108-11.
2001: Hille C J; Fox S H; Maneuf Y P; Crossman A R; Brotchie J M
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Experimental neurology 2001;172(1):189-98.
2001: Henry B; Fox S H; Crossman A R; Brotchie J M
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Experimental neurology 2001;171(1):139-46.
2001: Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman A R; Bioulac B; Brotchie J M; Gross C E
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(17):6853-61.
2001: Fox S H; Henry B; Hill M P; Peggs D; Crossman A R; Brotchie J M
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Movement disorders : official journal of the Movement Disorder Society 2001;16(4):642-50.
2001: Silverdale M A; McGuire S; McInnes A; Crossman A R; Brotchie J M
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Experimental neurology 2001;169(2):400-6.
2001: Bezard E; Ravenscroft P; Gross C E; Crossman A R; Brotchie J M
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.
Neurobiology of disease 2001;8(2):343-50.
2001: Bezard E; Crossman A R; Gross C E; Brotchie J M
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2001;15(6):1092-4.
2000: Nash J E; Fox S H; Henry B; Hill M P; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie J M; Crossman A R
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Experimental neurology 2000;165(1):136-42.
2000: Di Marzo V; Hill M P; Bisogno T; Crossman A R; Brotchie J M
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(10):1432-8.
2000: Crossman A R
Functional anatomy of movement disorders.
Journal of anatomy 2000;196 ( Pt 4)():519-25.
1999: Henry B; Fox S H; Peggs D; Crossman A R; Brotchie J M
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1999;14(5):744-53.
1999: Henry B; Crossman A R; Brotchie J M
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Experimental neurology 1999;155(2):204-20.
1998: Henry B; Crossman A R; Brotchie J M
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Experimental neurology 1998;151(2):334-42.
1998: Duty S; Henry B; Crossman A R; Brotchie J M
Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.
Experimental neurology 1998;150(2):223-34.
1998: Hughes N R; McKnight A T; Woodruff G N; Hill M P; Crossman A R; Brotchie J M
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):228-33.
1998: Henry B; Crossman A R; Brotchie J M
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.
Advances in neurology 1998;78():53-61.
1998: Brotchie J M; Henry B; Hille C J; Crossman A R
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.
Advances in neurology 1998;78():41-52.
1998: Crossman A R; Brotchie J M
Pathophysiology of dystonia.
Advances in neurology 1998;78():19-25.
1997: Maneuf Y P; Crossman A R; Brotchie J M
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Experimental neurology 1997;148(1):265-70.
1996: Maneuf Y P; Nash J E; Crossman A R; Brotchie J M
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
European journal of pharmacology 1996;308(2):161-4.
1996: Maneuf Y P; Duty S; Hille C J; Crossman A R; Brotchie J M
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Experimental neurology 1996;139(1):12-6.
1996: Maneuf Y P; Crossman A R; Brotchie J M
Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2.
Synapse (New York, N.Y.) 1996;22(4):382-5.
1995: Maneuf Y P; Mitchell I J; Crossman A R; Woodruff G N; Brotchie J M
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Brain research 1995;683(1):102-8.
1994: Griffiths P D; Perry R H; Crossman A R
A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease.
Neuroscience letters 1994;169(1-2):68-72.
1994: Maneuf Y P; Mitchell I J; Crossman A R; Brotchie J M
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Experimental neurology 1994;125(1):65-71.
1993: Page R D; Sambrook M A; Crossman A R
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Neuroscience 1993;55(1):147-65.
1993: Griffiths P D; Crossman A R
Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease.
Dementia (Basel, Switzerland) 1993;4(2):61-5.
1993: Graham W C; Sambrook M A; Crossman A R
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Brain research 1993;602(2):290-303.
1993: Brotchie J; Crossman A; Mitchell I; Duty S; Carroll C; Cooper A; Henry B; Hughes N; Maneuf Y
Chemical signalling in the globus pallidus in parkinsonism.
Progress in brain research 1993;99():125-39.
1992: Black M D; Carey F; Crossman A R; Relton J K; Rothwell N J
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat.
Brain research 1992;585(1-2):135-40.
1992: Mitchell I J; Boyce S; Sambrook M A; Crossman A R
A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Brain : a journal of neurology 1992;115 ( Pt 3)():809-24.
1992: Black M D; Crossman A R
Changes in dopamine D1 and D2 receptor binding in the substantia nigra following intrastriatal injection of a retrograde neurotoxin (volkensin).
Neuroscience letters 1992;134(2):180-2.
1992: Mitchell I J; Crossman A R; Liminga U; Andren P; Gunne L M
Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey.
Movement disorders : official journal of the Movement Disorder Society 1992;7(1):32-7.
1992: Aziz T Z; Peggs D; Agarwal E; Sambrook M A; Crossman A R
Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate.
British journal of neurosurgery 1992;6(6):575-82.
1991: Robertson R G; Graham W C; Sambrook M A; Crossman A R
Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus.
Brain research 1991;563(1-2):278-80.
1991: Graham W C; Hill D R; Woodruff G N; Sambrook M A; Crossman A R
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Neuroscience letters 1991;131(1):129-34.
1991: Brotchie J M; Crossman A R
D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents.
Experimental neurology 1991;113(2):171-81.
1991: Mitchell I J; Brotchie J M; Brown G D; Crossman A R
Modeling the functional organization of the basal ganglia. A parallel distributed processing approach.
Movement disorders : official journal of the Movement Disorder Society 1991;6(3):189-204.
1991: Aziz T Z; Peggs D; Sambrook M A; Crossman A R
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
Movement disorders : official journal of the Movement Disorder Society 1991;6(4):288-92.
1991: Brotchie J M; Mitchell I J; Sambrook M A; Crossman A R
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Movement disorders : official journal of the Movement Disorder Society 1991;6(2):133-8.
1990: Griffiths P D; Sambrook M A; Perry R; Crossman A R
Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease.
Journal of the neurological sciences 1990;100(1-2):131-6.
1990: Robertson R G; Clarke C A; Boyce S; Sambrook M A; Crossman A R
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Brain research 1990;531(1-2):95-104.
1990: Graham W C; Clarke C E; Boyce S; Sambrook M A; Crossman A R; Woodruff G N
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).
Brain research 1990;514(1):103-10.
1990: Graham W C; Crossman A R; Woodruff G N
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.
Brain research 1990;514(1):93-102.
1990: Mitchell I J; Luquin R; Boyce S; Clarke C E; Robertson R G; Sambrook M A; Crossman A R
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia.
Movement disorders : official journal of the Movement Disorder Society 1990;5(1):49-54.
1990: Boyce S; Clarke C E; Luquin R; Peggs D; Robertson R G; Mitchell I J; Sambrook M A; Crossman A R
Induction of chorea and dystonia in parkinsonian primates.
Movement disorders : official journal of the Movement Disorder Society 1990;5(1):3-7.
1990: Graham W C; Robertson R G; Sambrook M A; Crossman A R
Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism.
Life sciences 1990;47(18):PL91-7.
1990: Crossman A R
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Movement disorders : official journal of the Movement Disorder Society 1990;5(2):100-8.
1989: Graham W C; Robertson R G; Sambrook M A; Crossman A R
Extracellular amino acid levels in the globus pallidus of the conscious primate studied by intracerebral microdialysis.
British journal of pharmacology 1989;98 Suppl():819P.
1989: Mitchell I J; Jackson A; Sambrook M A; Crossman A R
The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies.
Brain : a journal of neurology 1989;112 ( Pt 6)():1533-48.
1989: Crossman A R; Peggs D; Boyce S; Luquin M R; Sambrook M A
Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Neuropharmacology 1989;28(11):1271-3.
1989: Augood S J; Emson P C; Mitchell I J; Boyce S; Clarke C E; Crossman A R
Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys.
Brain research. Molecular brain research 1989;6(1):85-92.
1989: Clarke C E; Boyce S; Robertson R G; Sambrook M A; Crossman A R
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Journal of the neurological sciences 1989;90(3):307-14.
1989: Robertson R G; Farmery S M; Sambrook M A; Crossman A R
Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus.
Brain research 1989;476(2):317-22.
1989: Mitchell I J; Clarke C E; Boyce S; Robertson R G; Peggs D; Sambrook M A; Crossman A R
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neuroscience 1989;32(1):213-26.
1989: Crossman A R
Neural mechanisms in disorders of movement.
Comparative biochemistry and physiology. A, Comparative physiology 1989;93(1):141-9.
1988: Crossman A R; Mitchell I J; Sambrook M A; Jackson A
Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea.
Brain : a journal of neurology 1988;111 ( Pt 5)():1211-33.
1988: Clarke C E; Boyce S; Sambrook M A; Stahl S M; Crossman A R
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Naunyn-Schmiedeberg's archives of pharmacology 1988;338(1):35-8.
1987: Graham W C; Crossman A R
Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input.
European journal of pharmacology 1987;142(3):479-81.
1987: Crossman A R; Clarke C E; Boyce S; Robertson R G; Sambrook M A
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1987;14(3 Suppl):428-35.
1987: Clarke C E; Sambrook M A; Mitchell I J; Crossman A R
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Journal of the neurological sciences 1987;78(3):273-80.
1987: Clarke C E; Boyce S; Sambrook M A; Crossman A R
Timing of levodopa therapy: evidence from MPTP-treated primates.
Lancet 1987;1(8533):625.
1987: Cross A J; Skan W J; Slater P; Mitchell I J; Crossman A R
Autoradiographic analysis of [3H]kainic acid binding in primate brain.
Journal of receptor research 1987;7(6):775-97.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Alan Crossman

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Activities & Behaviors

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Alan Crossman (preview)

All Publications